|
| |
Cambridge Antibody TechnologyCambridge Antibody Technology (CAT) is a biopharmaceutical company committed to developing human monoclonal antibody therapeutics to bring improvements to seriously ill patients' lives.CAT has strong financial foundations, good medium term prospects and significant opportunities for growth in the longer term.
| Contact Details: |
| Milstein BuildingGranta Park |
| Cambridge |
| Cambridgeshire |
| CB1 6GH |
| United Kingdom |
| Tel: | 44 (0)1223 471 471 |
| Fax: | 44 (0)1223 471 472 |
| Email: | info@cambridgeantibody.com |
| WWW: | www.cambridgeantibody.com/
|
|
Loading...
|
Recent Publications by Cambridge Antibody Technology: |  |
CAT-8015: a second-generation pseudomonas exotoxin A-based immunotherapy targeting CD22-expressing hematologic malignancies.
PURPOSE: To compare the in vitro and in vivo efficacy of CAT-8015, a... | 17th July, 2009
| Cambridge Antibody Technology, Inc., Palo Alto, California, USA.
| Clin Cancer Res. 2009 Feb 1;15(3):832-9.
DOI Direct Link |
In vitro DNA recombination by L-Shuffling during ribosome display affinity maturation of an anti-Fas antibody increases the population of improved variants.
The use of random mutagenesis in concert with protein display technologies... | 8th August, 2008
| Cambridge Antibody Technology, Milstein Building, Granta Park, Cambridge
| Protein Eng Des Sel. 2008 May;21(5):343-51.
DOI Direct Link |
Harnessing phage and ribosome display for antibody optimisation.
Therapeutic antibodies have become a major driving force for the... | 19th January, 2007
| Cambridge Antibody Technology, Milstein Building, Granta Park, Cambridge
| Trends Biotechnol. 2006 Nov;24(11):523-9. Epub 2006 Sep 26.
DOI Direct Link |
A potent human anti-eotaxin1 antibody, CAT-213: isolation by phage display and in vitro and in vivo efficacy.
The CC chemokine, eotaxin1 (CCL11) is an important regulator of eosinophil... | 11th January, 2007
| Cambridge Antibody Technology, Granta Park CB1 6GH, UK.
| J Pharmacol Exp Ther. 2006 Dec;319(3):1395-404. Epub 2006 Sep 14.
DOI Direct Link |
Affinity maturation of phage display antibody populations using ribosome display.
A comparison has been performed, using phage display or ribosome display,... | 12th September, 2006
| Cambridge Antibody Technology, Milstein Building, Granta Park, Cambridge
| J Immunol Methods. 2006 Jun 30;313(1-2):129-39. Epub 2006 May 11.
DOI Direct Link |
→View more Cambridge Antibody Technology research publications. |
Press Releases on Cambridge Antibody Technology:
|
 |
| Reportlinker Adds Monoclonal Antibody Therapies 2007: Competitive Landscape and Pipeline Insight |
5th November, 2009 |
Reportlinker |
NEW YORK, Nov. 5 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue.
Monoclonal Antibody Therapies 2007: Competitive Landscape and Pipeline
|
| Zyngenia, Inc. Raises $10 Million in Series A Funding |
4th November, 2009 |
Zyngenia, Inc. |
ROCKVILLE, Md., Nov. 4 /PRNewswire/ -- Zyngenia, Inc., a privately held biotherapeutics company focused on next-generation antibody drug development, today announced that it has secured $10 million
|
| Human Genome Sciences Begins Delivery of First-in-Class Anthrax Treatment to U.S. Strategic National Stockpile |
2nd February, 2009 |
Human Genome Sciences, Inc. |
- Delivery of 20,000 doses of ABthrax will bring at least $150 million in revenue to HGS -
ROCKVILLE, Md., Feb. 2 /PRNewswire-FirstCall/ -- Human Genome Sciences, Inc. (Nasdaq: HGSI) today announced
|
| MedImmune Expands R&D Capacity with New Research Facility in Cambridge, U.K. |
16th October, 2008 |
|
CAMBRIDGE, England, October 16 /PRNewswire/ -- MedImmune today announced the opening of a new, biologics research and
development (R&D) facility in Cambridge, the United Kingdom. Named after the
|
| Human Genome Sciences Reports Initial Results of Randomized Phase 2 Trial of HGS-ETR1 in Combination With Bortezomib in Advanced Multiple Myeloma |
2nd September, 2008 |
Human Genome Sciences, Inc. |
ROCKVILLE, Md., Sept. 2 /PRNewswire-FirstCall/ -- Human Genome Sciences,
Inc. (Nasdaq: HGSI) today reported initial topline results from an ongoing
randomized Phase 2 clinical trial of its TRAIL
|
BioPortfolio Ltd provides targeted e-mail address lists for the life science sector - we can enable you to contact around 11 individuals from Cambridge Antibody Technology using this service.  Contact BioPortfolio for a quote for a customised Excel verision of BioCorporate or BioEmail databases.
This page has been viewed 390 times since April 2007, the link to the organisation's website has been followed 64 times Recent Search Terms used to find this page: cambridge antibody tech | CAMBRIDGE ANTIBODY TECHNOLOGY | cambridge antibody technology building named after milstein | cambridge antibody technology revenue | cambridge antibody technology news 2006 | . Search for more companies in Cambridge Search for more companies in Cambridgeshire This site uses Thumbshots previews, resources from the NCBI applied. Maps are centred on zip/postcodes and should not be relied upon for exact building locations. Some information on this page has been collected automatically and may not have been verified.BioPortfolio search results for Cambridge Antibody Technology |
